BNTX · Intrinsic value
Is BioNTech SE (BNTX) overvalued or undervalued?
As of Oct 19, 2026, TickerWorth publishes a fair-value range of $64.92 – $64.92 for BioNTech SE (BNTX), against the delayed market price of $88.45: priced above our range. It is a range, not a single number, so we do not call it over- or undervalued. It is a model estimate, and every input behind it is sourced below.
Model by Miraaj Patel · generated from market data · Updated Oct 19, 2026 · How these pages are made
What is BNTX worth?
- Fair-value range
- $64.92 – $64.92
- Market price
- $88.45
- Gap to fair value
- —
- Verdict
- Priced above our range
Reverse DCF, on our cash-flow model rather than the range above: no growth rate up to 300%/yr justifies the price under these economics
What is BNTX's TickerWorth Score?
Scores lower than almost every company we compare it with
Compared with Healthcare companies in US
Its strongest point: strong balance sheet. Its weakest: growth is slow or negative.
- Value · 48 of 100
Cheaper than 48% of Healthcare companies in US
- Price vs worth · 29 of 100
- Quality · 33 of 100
More profitable than 33% of Healthcare companies in US
- Financial health · 68 of 100
Financially stronger than 68% of Healthcare companies in US
- Growth · 2 of 100
Growing faster than 2% of Healthcare companies in US
- Momentum · 30 of 100
Outperformed 30% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
Why BNTX gets a range, not one number
At a recent price of $88.45, BioNTech SE (BNTX) sits above every lens we ran: our valuation lenses put the business somewhere between $64.92 and $64.92 per share. They disagree too widely for us to state a single fair value. We publish the range rather than a midpoint because a number that precise would claim more than the methods can support. This is an educational model, not a price target or a recommendation.
Read the full reasoning
The valuation discounts BioNTech SE's projected free cash flows at a weighted-average cost of capital (WACC) of 11.0%, with a long-run terminal growth rate of 2.5%. About 64% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, BNTX's modeled DCF value ranges from about $0.63 to $24.09 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what BioNTech SE would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of BNTX's intrinsic value. Figures update as new filings and prices come in.
Every input behind BNTX's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | $2,969,520,000 |
| Base EBIT marginComputed — trailing operatingMargins, held roughly flat | 2.0% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | -2% → -0% → 1% → 3% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.2% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 1.25 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 251M |
| Market priceLast known price · as of 2026-10-19 19:30 UTC | $88.45 |
Change BNTX's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does BioNTech SE do?
What does it do?
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It operates in the Biotechnology industry (Healthcare sector), headquartered in Germany. The company employs roughly 7,807 people.
How does it make money?
The business turns $2.6B in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -806.6%), after a 77% gross margin on the products/services it sells. After all costs, taxes and interest, -63.6% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries moderate debt (1.8× equity), comfortably covers its short-term bills (7.8× current ratio), and is currently lossmaking.
Who at BNTX filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Sahin Ugur | Chief Executive Officer, 10% owner | Open-market sale | $3,453,371.82 | Form 4 for Sahin Ugur (opens sec.gov in a new tab) | |
| Sahin Ugur | Chief Executive Officer, 10% owner | Open-market sale | $2,492,483.40 | Form 4 for Sahin Ugur (opens sec.gov in a new tab) | |
| Sahin Ugur | Chief Executive Officer, 10% owner | Open-market sale | $2,300,632.80 | Form 4 for Sahin Ugur (opens sec.gov in a new tab) | |
| Sahin Ugur | Chief Executive Officer, 10% owner | Open-market sale | $2,032,995.30 | Form 4 for Sahin Ugur (opens sec.gov in a new tab) | |
| Sahin Ugur | Chief Executive Officer, 10% owner | Open-market sale | $7,000,646.40 | Form 4 for Sahin Ugur (opens sec.gov in a new tab) | |
| Sahin Ugur | Chief Executive Officer, 10% owner | Open-market sale | $1,644,323.30 | Form 4 for Sahin Ugur (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is BNTX's intrinsic value?
TickerWorth's valuation lenses put BioNTech SE (BNTX) between $64.92 and $64.92 per share, versus a market price of $88.45. They disagree too widely for us to state a single fair value, so we publish the range.
Is BNTX overvalued or undervalued?
At $88.45 the price sits above every lens we ran. We don't call BNTX overvalued or undervalued from a range this wide. This is an educational estimate, not advice.
What discount rate is used for BNTX?
A WACC of 11.0% and a terminal growth rate of 2.5%.
Is BioNTech stock undervalued?
TickerWorth's fair-value range for BioNTech SE (BNTX) is $64.92 – $64.92 against a market price of $88.45. Priced above our range. We publish a range here, not one number, so we do not call it over- or undervalued. This is a model estimate, not investment advice.
BioNTech (BNTX) DCF valuation and fair value
Our fair-value range for BioNTech SE (BNTX) is $64.92 – $64.92, built on a 11.0% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into BioNTech stock?
no growth rate up to 300%/yr justifies the price under these economics This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $88.45. A model estimate, not investment advice.
BioNTech (BNTX) insider trading
The most recent insider filing (SEC Form 4) for BioNTech SE (BNTX): Sahin Ugur, Chief Executive Officer, 10% owner, open-market sale on 2026-10-09. The latest filings are listed on this page. A disclosure, not a signal to trade.
Other ways into the coverage
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.